ELV

Business Context and Reporting Period

This summary covers the Annual Report on Form 10-K for Anthem, Inc. (now Elevance Health) for the fiscal year ended December 31, 2002. Anthem is the fifth largest publicly traded health benefits company in the United States, operating as an independent licensee of the Blue Cross Blue Shield Association (BCBSA) in nine states: Indiana, Kentucky, Ohio, Connecticut, New Hampshire, Maine, Colorado, Nevada, and Virginia. The company offers a diversified mix of managed care products (HMO, PPO, POS) and traditional indemnity products, alongside specialty services including pharmacy benefit management, dental, vision, and behavioral health.

A defining event for the period was the acquisition of Trigon Healthcare, Inc. on July 31, 2002, for approximately $4.0 billion. This transaction established a new Southeast operating segment in Virginia, adding approximately 2.5 million members and significantly expanding the company's geographic footprint.

Key Financial Metrics

Cash Flow: Net cash provided by operating activities was $991.1 million in 2002, a 51% increase from 2001. Net cash used in investing activities was $1,411.9 million, primarily driven by the Trigon acquisition ($785.5 million net cash outflow) and net purchases of investments.

Material Changes vs. Prior Period

• Revenue Growth: Total operating revenue increased by $2.87 billion (28%). This was driven by a 29% increase in premiums ($2.7 billion) and an 18% increase in administrative fees ($144.9 million). The growth was largely attributable to the Trigon acquisition and organic growth in fully-insured membership.
• Profitability Improvement: Net income rose 60% to $549.1 million. Operating gain more than doubled to $644.5 million. The operating margin expanded to 5.0% from 3.2%, reflecting improved underwriting results and lower medical cost trends than anticipated.
• Medical Cost Trends: The benefit expense ratio improved by 210 basis points. Aggregate cost of care trends for the rolling 12-month period were approximately 12%, driven by professional services and outpatient costs. Pharmacy costs increased by approximately 16% due to new high-cost drugs and increased utilization.
• Membership Expansion: Total membership grew by 3.2 million (40%) to 11.05 million. On a same-store basis (excluding Trigon), membership grew 8% (621,000 members), with significant gains in National Accounts (BlueCard) and Individual segments.
• Debt Structure: Long-term debt increased significantly to fund the Trigon acquisition. In July 2002, the company issued $950 million in senior unsecured notes ($150 million due 2005 and $800 million due 2012).

Guidance, Outlook, and Risks

Outlook and Synergies: Management expects to achieve $40.0 million to $50.0 million in synergies from the Trigon acquisition in 2003, with at least $75.0 million by 2004. The company aims to maintain a debt-to-total-capital ratio of 25% or less to optimize the cost of capital.

Strategic Initiatives:

• Product Design: Continued implementation of three-tier drug programs to manage pharmacy costs; currently implemented for approximately 66% of members.
• Acquisitions: A pending acquisition of Blue Cross and Blue Shield of Kansas (BCBS-KS) for $190.0 million is subject to regulatory approval, currently under appeal in the Kansas Supreme Court.
• Capital Allocation: A new $500.0 million stock repurchase program was authorized in January 2003, replacing a completed $400.0 million program.

Risks and Contingencies:

• Regulatory Environment: The company faces significant regulation regarding small group reform, Medicare reimbursement rates (which have been reduced by federal legislation), and HIPAA compliance. Changes in these areas could impact profitability.
• Legal Proceedings: Anthem is involved in various class-action lawsuits, including a Multi-District Litigation (MDL) in Florida alleging improper claims processing and RICO violations. Additionally, the Ohio Supreme Court reinstated a $30.0 million punitive damages award in the Dardinger case, though the company has not decided whether to appeal to the U.S. Supreme Court.
• Government Audits: Ongoing reviews by the Office of Inspector General (OIG) regarding Medicare fiscal intermediary operations and the Federal Employee Program (FEP) could result in fines or penalties, though management believes these will not be material.
• Investment Risk: The company holds $5.9 billion in investments, primarily fixed maturity securities. It is exposed to interest rate risk and credit quality risk, though the portfolio is well-diversified with an average credit rating of AA.

Key Facts for Investor Verification

• Trigon Integration: Verify the realization of projected synergies ($40M-$50M in 2003) and the successful integration of the Southeast segment's operations and systems.
• Medical Cost Trends: Monitor the sustainability of the 12% aggregate cost of care trend and the effectiveness of three-tier drug programs in curbing the 16% pharmacy cost increase.
• BCBS-KS Acquisition: Track the outcome of the Kansas Supreme Court appeal regarding the $190 million acquisition of Blue Cross and Blue Shield of Kansas.
• Legal Exposure: Assess the potential financial impact of the Dardinger case appeal and the ongoing MDL litigation regarding claims processing practices.
• Regulatory Changes: Evaluate the impact of potential changes in Medicare reimbursement methodologies and state-level small group reform statutes on future premium rates and underwriting flexibility.
• Debt Servicing: Confirm the company's ability to maintain its target debt-to-total-capital ratio of 25% or less given the increased debt load from the Trigon acquisition.